COMPASS Pathways plc

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Are revenue and earnings forecast to grow?

Earnings are forecast to decline by an average of 15.5% per year for the next 3 years
Section 4.1
Fail
Are they forecast to achieve profitability?

Currently unprofitable and not forecast to become profitable over the next 3 years
Section 4.1
Pass
Are they in a good financial position?

They have sufficient cash for at least 1 year of operations
Section 6.4
Pass
Is their dividend sustainable?

They do not pay a dividend
Section 7.0
Pass
Is their share price liquid and stable?

Share price has been stable over the past 3 months
Section 2.1
Pass
Do they have sufficient financial data available?

They have sufficient analyst coverage
Section 4.0
Pass
Are there any concerning recent events?

No concerning events detected
Section 2.1
Pass
Do they have a meaningful market capitalization?

Market cap is meaningful ($1B)
Section 10.0
Pass
Do they have negative shareholders equity?

CMPS does not have negative shareholders equity.